by Laia Ruiz Mingote, Dorothy Namutamba, Francis Apina et al.
The Lancet, Early Online Publication, 11 July 2014
As the first new drug from a novel class approved to treat tuberculosis in more than 40 years, bedaquiline’s implications for improving treatment of drug-resistant tuberculosis and possible application to create shorter first-line regimens for treatment of drug-susceptible tuberculosis is still unclear. Community voices on bedaquiline’s use to treat drug-resistant tuberculosis and future development as a potential treatment for drug-susceptible disease have been largely unheard. The authors provide a community perspective on this issue and list seven questions concerning bedaquiline’s safety that researchers should answer before the launch of clinical trials of bedaquiline for drug-susceptible tuberculosis.